drugset / Trial / NCT06265350
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
RandomizedParallel-groupOpen-labelTreatment
Summary
This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.
Timeline
- Start
- 2024-02-02
- Primary completion
- 2026-01-30
- Completion
- 2027-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Cadonilimab | Monoclonal antibody | 375 mg | Intravenous |